SCHEMBL105698

SCHEMBL105698

COCC(C)(OC(N)=O)c1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.70
KDR P35968 20/20 0.70
PLK4 O00444 1/20 0.70
MAP4K4 O95819 1/20 0.70
ABL1 P00519 1/20 0.70
LCK P06239 1/20 0.70
FYN P06241 1/20 0.70
LYN P07948 1/20 0.70
HCK P08631 1/20 0.70
PDGFRB P09619 1/20 0.70
BCR P11274 1/20 0.70
SRC P12931 1/20 0.70
AXL P30530 1/20 0.70
FLT3 P36888 1/20 0.70
ABL2 P42684 1/20 0.70
FRK P42685 1/20 0.70
SYK P43405 1/20 0.70
MST1R Q04912 1/20 0.70
DDR1 Q08345 1/20 0.70
MERTK Q12866 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105701 0.84 MET (0.75) METKDRPLK4MAP4K4ABL1
SCHEMBL104141 0.83 MET (0.82) METKDRPLK4MAP4K4ABL1
SCHEMBL104578 0.83 MET (0.77) METKDRPLK4MAP4K4ABL1
Glesatinib SCHEMBL29351360 0.83 MET (1.00) METKDRPLK4MAP4K4ABL1
Glesatinib SCHEMBL106319 0.83 MET (1.00) METKDRPLK4MAP4K4ABL1
SCHEMBL105699 0.82 MET (0.71) METKDRPLK4MAP4K4ABL1
SCHEMBL2536266 0.82 MET (0.89) METKDRPLK4MAP4K4ABL1
SCHEMBL3432803 0.82 MET (0.45) METKDRPLK4MAP4K4ABL1
SCHEMBL106729 0.82 MET (0.73) METKDRPLK4MAP4K4ABL1
SCHEMBL2533066 0.81 MET (0.73) METKDRPLK4MAP4K4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 EP disclosed
EP-2426108-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MethylGene Inc. (CA) 2012-03-07 EP disclosed